当前位置: X-MOL 学术Mol. Cancer Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
FGFR inhibition enhances sensitivity to radiation in non-small cell lung cancer.
Molecular Cancer Therapeutics ( IF 5.7 ) Pub Date : 2020-05-05 , DOI: 10.1158/1535-7163.mct-19-0931
Gopika SenthilKumar 1 , Michael M Fisher 1 , Justin H Skiba 1 , Margot C Miller 1 , Sean R Brennan 1 , Saakshi Kaushik 1 , Samantha T Bradley 1 , Colin A Longhurst 2 , Darya Buehler 3 , Kwangok P Nickel 1 , Gopal Iyer 1 , Randall J Kimple 1 , Andrew M Baschnagel 1
Affiliation  

FGFRs are commonly altered in non–small cell lung cancer (NSCLC). FGFRs activate multiple pathways including RAS/RAF/MAPK, PI3K/AKT, and STAT, which may play a role in the cellular response to radiation. We investigated the effects of combining the selective FGFR 1-3 tyrosine kinase inhibitor AZD4547 with radiation in cell line and xenograft models of NSCLC. NSCLC cell lines were assessed with proliferation, clonogenic survival, apoptosis, autophagy, cell cycle, and DNA damage signaling and repair assays. In vivo xenografts and IHC were used to confirm in vitro results. NSCLC cell lines demonstrated varying degrees of FGFR protein and mRNA expression. In vitro clonogenic survival assays showed radiosensitization with AZD4547 in two NSCLC cell lines. In these two cell lines, an increase in apoptosis and autophagy was observed with combined radiation and AZD4547. The addition of AZD4547 to radiation did not significantly affect γH2AX foci formation. Enhanced xenograft tumor growth delay was observed with the combination of radiation and AZD4547 compared with radiation or drug alone. IHC results revealed inhibition of pMAPK and pS6 and demonstrated an increase in apoptosis in the radiation plus AZD4547 group. This study demonstrates that FGFR inhibition by AZD4547 enhances the response of radiation in FGFR-expressing NSCLC in vitro and in vivo model systems. These results support further investigation of combining FGFR inhibition with radiation as a clinical therapeutic strategy.

中文翻译:

FGFR 抑制增强了非小细胞肺癌对辐射的敏感性。

FGFR 通常在非小细胞肺癌 (NSCLC) 中发生改变。FGFRs 激活多种途径,包括 RAS/RAF/MAPK、PI3K/AKT 和 STAT,它们可能在细胞对辐射的反应中发挥作用。我们研究了选择性 FGFR 1-3 酪氨酸激酶抑制剂 AZD4547 与放疗在 NSCLC 细胞系和异种移植模型中的效果。NSCLC 细胞系通过增殖、克隆存活、细胞凋亡、自噬、细胞周期和 DNA 损伤信号传导和修复分析进行评估。体内异种移植物和 IHC 用于确认体外结果。NSCLC 细胞系表现出不同程度的 FGFR 蛋白和 mRNA 表达。体外克隆存活试验显示 AZD4547 在两种 NSCLC 细胞系中具有放射增敏作用。在这两个细胞系中,结合辐射和AZD4547观察到细胞凋亡和自噬增加。将 AZD4547 添加到辐射中并没有显着影响 γH2AX 病灶的形成。与单独放疗或药物相比,放疗和 AZD4547 的组合增强了异种移植肿瘤的生长延迟。IHC 结果显示 pMAPK 和 pS6 受到抑制,并证明在辐射加 AZD4547 组中细胞凋亡增加。该研究表明,AZD4547 对 FGFR 的抑制增强了体外和体内模型系统中表达 FGFR 的 NSCLC 的辐射反应。这些结果支持将 FGFR 抑制与放射相结合作为临床治疗策略的进一步研究。与单独放疗或药物相比,放疗和 AZD4547 的组合增强了异种移植肿瘤的生长延迟。IHC 结果显示 pMAPK 和 pS6 受到抑制,并证明在辐射加 AZD4547 组中细胞凋亡增加。该研究表明,AZD4547 对 FGFR 的抑制增强了体外和体内模型系统中表达 FGFR 的 NSCLC 的辐射反应。这些结果支持将 FGFR 抑制与放射相结合作为临床治疗策略的进一步研究。与单独放疗或药物相比,放疗和 AZD4547 的组合增强了异种移植肿瘤的生长延迟。IHC 结果显示 pMAPK 和 pS6 受到抑制,并证明在辐射加 AZD4547 组中细胞凋亡增加。该研究表明,AZD4547 对 FGFR 的抑制增强了体外和体内模型系统中表达 FGFR 的 NSCLC 的辐射反应。这些结果支持将 FGFR 抑制与放射相结合作为临床治疗策略的进一步研究。该研究表明,AZD4547 对 FGFR 的抑制增强了体外和体内模型系统中表达 FGFR 的 NSCLC 的辐射反应。这些结果支持将 FGFR 抑制与放射相结合作为临床治疗策略的进一步研究。该研究表明,AZD4547 对 FGFR 的抑制增强了体外和体内模型系统中表达 FGFR 的 NSCLC 的辐射反应。这些结果支持将 FGFR 抑制与放射相结合作为临床治疗策略的进一步研究。
更新日期:2020-05-05
down
wechat
bug